Edition:
India

Ophthotech Corp (OPHT.OQ)

OPHT.OQ on NASDAQ Stock Exchange Global Select Market

2.68USD
16 Jul 2018
Change (% chg)

$-0.02 (-0.74%)
Prev Close
$2.70
Open
$2.69
Day's High
$2.69
Day's Low
$2.68
Volume
3,176
Avg. Vol
76,891
52-wk High
$4.49
52-wk Low
$2.25

Latest Key Developments (Source: Significant Developments)

Ophthotech Enters Gene Therapy Agreements With University Of Florida And University Of Pennsylvania
Thursday, 7 Jun 2018 

June 7 (Reuters) - Ophthotech Corp ::OPHTHOTECH ENTERS INTO GENE THERAPY AGREEMENTS WITH THE UNIVERSITY OF FLORIDA AND THE UNIVERSITY OF PENNSYLVANIA.OPHTHOTECH CORP - PHASE 1/2 CLINICAL TRIAL EXPECTED TO INITIATE IN EARLY 2020.OPHTHOTECH - AS PART OF COLLABORATION, CO TO WORK IN PARTNERSHIP WITH SCIENTISTS IN GENE THERAPY FOR ORPHAN RETINAL DISEASES.  Full Article

Ophthotech Completes Patient Recruitment In A Mid-Stage Trial Of Its Eye Drug Zimura
Tuesday, 1 May 2018 

May 1 (Reuters) - Ophthotech Corp ::OPHTHOTECH COMPLETES PATIENT RECRUITMENT IN THE PHASE 2A CLINICAL TRIAL OF ZIMURA® IN COMBINATION WITH ANTI-VEGF THERAPY IN WET AGE-RELATED MACULAR DEGENERATION.OPHTHOTECH CORP - INITIAL TOP-LINE DATA EXPECTED BY END OF 2018.OPHTHOTECH CORP - WILL EVALUATE DATA AT MONTH 6.  Full Article

Ophthotech Q3 earnings per share $5.25
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Ophthotech Corp ::Ophthotech reports third quarter 2017 financial and operating results.Q3 earnings per share $5.25.Q3 earnings per share view $2.67 -- Thomson Reuters I/B/E/S.Ophthotech Corp - ‍collaboration revenue was $206.7 million for quarter ended September 30, 2017, compared to $1.7 million for same period in 2016​.Ophthotech Corp - ‍as of September 30, 2017, company had $180.2 million in cash and cash equivalents​.Ophthotech Corp - ‍expects a 2017 year end cash balance of between $155 million and $165 million​.  Full Article

Ophthotech says Fovista phase 3 trial did not meet primary endpoint
Monday, 12 Dec 2016 

Ophthotech Corp : pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal phase 3 clinical trials . addition of Fovista to monthly Lucentis regimen did not result in benefit as measured by mean change in visual acuity at 12 month time point . based on preliminary analysis of safety data, Fovista and Lucentis monotherapy were generally well tolerated after one year of treatmen .Ophthotech announces results from pivotal phase 3 trials of Fovista in wet age-related macular degeneration.  Full Article

Ophthotech Q2 loss per share $0.85
Wednesday, 3 Aug 2016 

Ophthotech Corp : Q2 loss per share $0.85 . Q2 earnings per share view $-1.05 -- Thomson Reuters I/B/E/S .Says collaboration revenue was $28.2 million for quarter ended June 30, 2016, compared to $1.6 million for same period in 2015.  Full Article

BRIEF-Ophthotech Reports Q1 Loss Per Share Of $0.36

* OPHTHOTECH REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS